Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer

World Journal of Gastroenterology

Volumn 10, Issue 11, 2004, Pages 1675-1677

  Jiang, Jing Ting ^a   Wu, Chang Ping ^a   Deng, Hai Feng ^a   Lu, Ming Yang ^a   Wu, Jun ^a   Zhang, Hong Yu ^a   Sun, Wen Hui ^a   Ji, Mei ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CANCER GROWTH FACTOR; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CANCER STAGING; COLORIMETRY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TISSUE DIFFERENTIATION; TISSUE DISTRIBUTION; TUMOR LOCALIZATION;

EID: 2942744794     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i11.1675     Document Type: Article

References (31)

1. Barbe L, Ponsot P, Vilgrain V, Terris B, Flejou JF, Sauvanet A, Belghiti J, Hammel P, Ruszniewski P, Bernades P. Intraductal papillary mucinous tumors of the pancreas. Clinical and morphological aspects in 30 patients. Gastroenterol Clin Biol 1997; 21: 278-286
2. Love L, Fizzotti G, Damascelli B, Ceglia E, Garbagnati F, Milella M. Pancreatic tumor imaging by III generation CT, gray-scale ultrasound and improved angiography. Tumori 1980; 66: 357-372
3. Sahmoun AE, D'Agostino RA Jr, Bell RA, Schwenke DC. International variation in pancreatic cancer mortality for the period 1955-1998. Eur J Epidemiol 2003; 18: 801-816
4. Burcharth F, Trillingsgaard J, Olsen SD, Moesgaard F, Federspiel B, Struckmann JR. Resection of cancer of the body and tail of the pancreas.Hepatogastroenterology 2003; 50: 563-566
5. Soga J. Primary endocrinomas (carcinoids and variant neoplasms) of the gallbladder. A statistical evaluation of 138 reported cases. J Exp Clin Cancer Res 2003; 22: 5-15
6. Pingpank JF Jr, Hoffman JP, Sigurdson ER, Ross E, Sasson AR, Eisenberg BL. Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms. Am Surg 2002; 68: 337-340
7. Birk D, Schoenberg MH, Gansauge F, Formentini A, Fortnagel G, Beger HG. Carcinoma of the head of the pancreas arising from the uncinate process. Br J Surg 1998; 85: 498-501
8. Standop J, Schneider MB, Ulrich A, Pour PM. Experimental animal models in pancreatic carcinogenesis: lessons for human pancreatic cancer. Dig Dis 2001; 19: 24-31
9. Berberat P, Friess H, Kashiwagi M, Beger HG, Buchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999; 23: 882-887
10. Zalatnai A. Pancreatic cancer - a continuing challenge in oncology. Pathol Oncol Res 2003; 9: 252-263
11. Shore S, Raraty MG, Ghaneh P, Neoptolemos JP. Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 2003; 18: 1049-1069
12. Otsuki M. Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol 2003; 38: 315-326
13. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C, Ducreux M, Briantais MJ, Buffet C, Soussi T. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995; 36: 455-458
14. Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, Ord S, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL, Yeo CJ. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 1999; 44: 1039-1046
15. Vestergaard EM, Wolf H, Orntoft TF. Increased concentrations of genotype-interpreted Ca 19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium. Clin Chem 1998; 44: 197-204
16. a: a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 2002; 49: 303-311
17. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983; 43: 5489-5492
18. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138: 951-956
19. Banfi G, Zerbi A, Pastori S, Parolini D, Di Carlo V, Bonini P. Behavior of tumor markers CA19.9, CA195, CAM43, CA242 and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem 1993; 39: 420-423
20. Ichihara T, Nomoto S, Takeda S, Nagura H, Sakamoto J, Kondo K, Horisawa M, Nakao A. Clinical usefulness of the immunostaining of the tumor markers in pancreatic cancer. Hepatogastroenterology 2001; 48: 939-943
21. Frebourg T, Bercoff E, Manchon N, Senant J, Basuyau JP, Breton P, Janvresse A, Brunelle P, Bourreille J. The evaluation of CA19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62: 2287-2290
22. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-1417
23. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-1016
24. Masaki T, Ohkawa S, Hirokawa S, Miyakawa K, Tamai S, Tarao K. A case of advanced pancreatic cancer showing remarkable response to gemcitabine treatment. Gan To Kagaku Ryoho 2003; 30: 1333-1336
25. Kamisawa T, Tu Y, Egawa N, Ishiwata J, Tsuruta K, Okamoto A, Hayashi Y, Koike M, Yamaguchi T. Ductal and acinar differentiation in pancreatic endocrine tumors. Dig Dis Sci 2002; 47: 2254-2261
26. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004; 10: 860-868
27. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003; 138: 951-956
28. Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y, Xuezhi W. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002; 25: 336-341
29. Mu DQ, Wang GF, Peng SY. p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis. World J Gastroenterol 2003; 9: 1815-1818
30. Metsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 1998; 65: 1405-1409
31. Frebourg T, Bercoff E, Mouchon N, Senant J, Basuyau JP, Breton P, Janvresse A, Brunelle P, Bourreille J. The evaluation CA19-9 antigen level in the early detection of pancreatic cancer. Cancer 1988; 62: 2287-2290